#Weight loss medication

Two Case Reports Link Abrupt Tirzepatide Discontinuation to Mania and Psychosis

Two Case Reports Link Abrupt Tirzepatide Discontinuation to Mania and Psychosis

Two men were hospitalized with acute psychiatric symptoms after abruptly stopping tirzepatide, the active ingredient in Mounjaro and Zepbound, according to case studies published in The Primary Care Companion for Central Nervous System Disorders. One patient showed signs of psychosis, including hallucinations and a rare delusion that he was dead, while the other was diagnosed with a manic episode. The authors do not claim the drug withdrawal caused the symptoms. They say the timing is worth attention and that prescribers should consider recent changes in GLP-1 medication when evaluating patients with new mood or psychotic symptoms.

Cheaper GLP-1 Generics Arrive, and a Global Access Fight May Follow

Cheaper GLP-1 Generics Arrive, and a Global Access Fight May Follow

Lower-cost generic versions of semaglutide, the drug sold as Wegovy by Novo Nordisk for obesity, have begun reaching some countries and will soon arrive in others. At the same time, drugmakers are racing to develop newer GLP-1 medicines that are forecast to be more effective, cause fewer side effects and be easier to administer. London School of Economics professor Ken Shadlen, who studies the politics of pharmaceutical and health regulation, warns that obesity medications could become the next major battleground over access to medicines in lower-income countries. The shifts could put weight-loss treatment within reach of more people, but the path to access is far from settled.